Neurological-Focused Pharmaceutical Company, Lundbeck, Continues Use of Medidata Clinical Cloud® with Multi-Year Partnership
October 05 2017 - 8:30AM
Business Wire
Copenhagen-based Company to Leverage Medidata’s
Cloud Technology to Accelerate Psychiatric and Neurological
R&D
Medidata (NASDAQ: MDSO), the leading global provider of
cloud-based solutions and data analytics for clinical research,
today announced that pharmaceutical firm H. Lundbeck A/S
(Lundbeck), has entered a multi-year partnership to continue its
use of the Medidata Clinical Cloud® and utilize operational
capabilities to power their next generation global clinical
trials.
The continued partnership allows Lundbeck to leverage integral
parts of the Medidata Clinical Cloud platform that provide key
capabilities in study conduct and site support, including Medidata
Rave®, Coder®, and TSDV (Targeted Source Document
Verification).
A Medidata customer since 2007, Lundbeck is a global
pharmaceutical company specializing in psychiatric and neurological
disorders. By continuing its use of Medidata Rave®, the
industry-leading solution for capturing, managing and reporting
data, Coder®, and TSDV (Targeted Source Document Verification),
Lundbeck will increase the quality of its clinical research efforts
by more accurately evaluating clinical data, streamlining
workflows, and ultimately, optimizing trial results.
“We’re proud to be a long term partner to Lundbeck, an
innovative organization bringing together deep industry expertise
in drug development activities for neurological disorders,” said
Mike Capone, chief operating officer at Medidata. “We look forward
to continuing to power their mission to tackle unmet needs for
patients living with serious medical conditions.”
About Medidata
Medidata is reinventing global drug and medical device
development by creating the industry's leading cloud-based
solutions for clinical research. Through our advanced applications
and intelligent data analytics, Medidata helps advance the
scientific goals of life sciences customers worldwide, including
over 850 global pharmaceutical companies, biotech, diagnostic and
device firms, leading academic medical centers, and contract
research organizations.
The Medidata Clinical Cloud® brings a new level of quality and
efficiency to clinical trials that empower our customers to make
more informed decisions earlier and faster. Our unparalleled
clinical trial data assets provide deep insights that pave the way
for future growth. The Medidata Clinical Cloud is the primary
technology solution powering clinical trials for 18 of the world's
top 25 global pharmaceutical companies and is used by 18 of the top
25 medical device developers—from study design and planning through
execution, management and reporting.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171005005563/en/
Medidata SolutionsInvestors:Anthony D’Amico, +1
732-767-4331adamico@mdsol.comorMedia:Erik Snider, +1
646-362-2997esnider@mdsol.com
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Apr 2023 to Apr 2024